HighTower Advisors’s NovoCure NVCR Stock Holding History

HighTower Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-100	Closed	-$1K	–	3357
2021 Q2	$1K	Buy	+100	New	+$19.5K	﹤0.01%	3112
2021 Q1	–	Sell	-1	Closed	-$3K	–	3204
2020 Q4	$3K	Sell	1 -499	-100%	-$68.3K	﹤0.01%	2552
2020 Q3	$10K	Buy	+500	New	+$40K	﹤0.01%	2429
2020 Q2	–	Sell	-700	Closed	-$1K	–	2503
2020 Q1	$1K	Buy	+700	New	+$55.3K	﹤0.01%	2198
2019 Q1	–	Sell	-100	Closed	-$1K	–	2384
2018 Q4	$1K	Hold	100	–	–	﹤0.01%	2192
2018 Q3	$1K	Sell	100 -100	-50%	-$3.98K	﹤0.01%	2268
2018 Q2	$1K	Sell	200 -700	-78%	-$19.5K	﹤0.01%	2220
2018 Q1	$1K	Buy	+900	New	+$19.4K	﹤0.01%	2174

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

HighTower Advisors's NVCR Position: Q2 2023 in Review

HighTower Advisors sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 4,242 shares — an estimated $256K sold.

HighTower Advisors first reported a position in NVCR in Q1 2018 and held it in 21 quarters. The position peaked at $1.59M in Q2 2021. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

HighTower Advisors reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
HighTower Advisors sold 4,242 NovoCure shares in Q2 2023, an estimated $256K.
HighTower Advisors first reported a position in NovoCure in Q1 2018 and held it in 21 quarters.
HighTower Advisors's NovoCure position peaked at $1.59M in Q2 2021.
267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on HighTower Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.